File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

TitleUsing siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
Authors
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/nm
Citation
Nature Medicine, 2005, v. 11 n. 9, p. 944-951 How to Cite?
AbstractDevelopment of therapeutic agents for severe acute respiratory syndrome (SARS) viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of SARS coronavirus (SCV) in vitro were further evaluated for efficacy and safety in a rhesus macaque (Macaca mulatta) SARS model using clinically viable delivery while comparing three dosing regimens. Observations of SARS-like symptoms, measurements of SCV RNA presence and lung histopathology and immunohistochemistry consistently showed siRNA-mediated anti-SARS efficacy by either prophylactic or therapeutic regimens. The siRNAs used provided relief from SCV infection-induced fever, diminished SCV viral levels and reduced acute diffuse alveoli damage. The 10-40 mg/kg accumulated dosages of siRNA did not show any sign of siRNA-induced toxicity. These results suggest that a clinical investigation is warranted and illustrate the prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents.
Persistent Identifierhttp://hdl.handle.net/10722/78987
ISSN
2015 Impact Factor: 30.357
2015 SCImago Journal Rankings: 13.959
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLi, BJen_HK
dc.contributor.authorTang, Qen_HK
dc.contributor.authorCheng, Den_HK
dc.contributor.authorQin, Cen_HK
dc.contributor.authorXie, FYen_HK
dc.contributor.authorWei, Qen_HK
dc.contributor.authorXu, Jen_HK
dc.contributor.authorLiu, Yen_HK
dc.contributor.authorZheng, BJen_HK
dc.contributor.authorWoodle, MCen_HK
dc.contributor.authorZhong, Nen_HK
dc.contributor.authorLu, PYen_HK
dc.date.accessioned2010-09-06T07:49:13Z-
dc.date.available2010-09-06T07:49:13Z-
dc.date.issued2005en_HK
dc.identifier.citationNature Medicine, 2005, v. 11 n. 9, p. 944-951en_HK
dc.identifier.issn1078-8956en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78987-
dc.description.abstractDevelopment of therapeutic agents for severe acute respiratory syndrome (SARS) viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of SARS coronavirus (SCV) in vitro were further evaluated for efficacy and safety in a rhesus macaque (Macaca mulatta) SARS model using clinically viable delivery while comparing three dosing regimens. Observations of SARS-like symptoms, measurements of SCV RNA presence and lung histopathology and immunohistochemistry consistently showed siRNA-mediated anti-SARS efficacy by either prophylactic or therapeutic regimens. The siRNAs used provided relief from SCV infection-induced fever, diminished SCV viral levels and reduced acute diffuse alveoli damage. The 10-40 mg/kg accumulated dosages of siRNA did not show any sign of siRNA-induced toxicity. These results suggest that a clinical investigation is warranted and illustrate the prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents.en_HK
dc.languageengen_HK
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/nmen_HK
dc.relation.ispartofNature Medicineen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGenome, Viralen_HK
dc.subject.meshLung - drug effects - pathology - virologyen_HK
dc.subject.meshMacaca mulattaen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMolecular Sequence Dataen_HK
dc.subject.meshRNA, Small Interfering - therapeutic useen_HK
dc.subject.meshSARS Virus - drug effectsen_HK
dc.subject.meshSevere Acute Respiratory Syndrome - drug therapy - pathology - prevention & controlen_HK
dc.titleUsing siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaqueen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1078-8956&volume=11&spage=944&epage=951&date=2005&atitle=Using+siRNA+in+prophylactic+and+therapeutic+regimens+against+SARS+coronavirus+in+Rhesus+macaqueen_HK
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_HK
dc.identifier.authorityZheng, BJ=rp00353en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/nm1280en_HK
dc.identifier.pmid16116432-
dc.identifier.scopuseid_2-s2.0-24744466699en_HK
dc.identifier.hkuros105591en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-24744466699&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume11en_HK
dc.identifier.issue9en_HK
dc.identifier.spage944en_HK
dc.identifier.epage951en_HK
dc.identifier.isiWOS:000231724700021-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLi, BJ=17135119600en_HK
dc.identifier.scopusauthoridTang, Q=8897783800en_HK
dc.identifier.scopusauthoridCheng, D=36679655600en_HK
dc.identifier.scopusauthoridQin, C=7102688076en_HK
dc.identifier.scopusauthoridXie, FY=7202420808en_HK
dc.identifier.scopusauthoridWei, Q=7201692917en_HK
dc.identifier.scopusauthoridXu, J=7407005993en_HK
dc.identifier.scopusauthoridLiu, Y=8897784500en_HK
dc.identifier.scopusauthoridZheng, BJ=7201780588en_HK
dc.identifier.scopusauthoridWoodle, MC=7005235996en_HK
dc.identifier.scopusauthoridZhong, N=7102137996en_HK
dc.identifier.scopusauthoridLu, PY=7402293148en_HK
dc.identifier.citeulike312418-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats